Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea · Delayed Price · Currency is KRW 15,140
-890 (-5.55%)
Oct 12, 2026, 3:30 PM KST
Kolon TissueGene Market Cap
Kolon TissueGene has a market cap or net worth of 1.29 trillion as of October 12, 2026. It is the 10,408th most valuable company in the world and the 270th biggest in South Korea. Its market cap has decreased by 65.56% in one year.
Market Cap
1.29T
Enterprise Value
1.25T
Revenue
4.80B
Global Rank
Country Rank
#270 South Korea
PE Ratio
n/a
ChartMarket Cap Chart
Since November 6, 2017, Kolon TissueGene's market cap has decreased from 2.58T to 1.29T, a decrease of -50.10%. That is a compound annual growth rate of -7.48%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 12, 2026 | 1.29T | -80.58% |
| Dec 30, 2025 | 6.62T | 258.54% |
| Dec 30, 2024 | 1.85T | 181.73% |
| Dec 28, 2023 | 655.80B | 7.08% |
| Dec 29, 2022 | 612.43B | -76.74% |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 6, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| LigaChem Biosciences | 2.70T |
| ABL Bio | 2.69T |
| OliX Pharmaceuticals | 2.67T |
| Voronoi | 2.51T |
| Peptron | 2.13T |
| Hugel | 1.97T |
| D&D Pharmatech | 1.96T |
| Komipharm International | 821.80B |